UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Fewer COVID-19 neurological complications with dexamethasone and remdesivir

Grundmann, Alexander; Wu, Chieh-Hsi; Hardwick, Marc; Baillie, J Kenneth; Openshaw, Peter Jm; Semple, Malcolm G; Böhning, Dankmar; ... ISARIC4C investigators, .; + view all (2023) Fewer COVID-19 neurological complications with dexamethasone and remdesivir. Annals of Neurology , 93 (1) pp. 88-102. 10.1002/ana.26536. Green open access

[thumbnail of Annals of Neurology - 2022 - Grundmann - Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir.pdf]
Preview
Text
Annals of Neurology - 2022 - Grundmann - Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir.pdf

Download (753kB) | Preview

Abstract

OBJECTIVE: To assess the impact of treatment with dexamethasone, remdesivir or both on neurological complications in acute COVID-19. METHODS: We used observational data from the International Severe Acute and emerging Respiratory Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK). Hospital inpatients aged ≥18 years with laboratory-confirmed SARS-CoV-2 infection admitted between 31 January 2020 and 29 June 2021 were included. Treatment allocation was non-blinded and performed by reporting clinicians. A propensity scoring methodology was used to minimize confounding. Treatment with remdesivir, dexamethasone or both was assessed against standard of care. The primary outcome was a neurological complication occurring at the point of death, discharge, or resolution of the COVID-19 clinical episode. RESULTS: Out of 89,297 hospital inpatients, 64,088 had severe COVID-19 and 25,209 had non-hypoxic COVID-19. Neurological complications developed in 4.8% and 4.5% respectively. In both groups, neurological complications associated with increased mortality, ICU admission, worse self-care on discharge and time to recovery. In severe COVID-19, treatment with dexamethasone (n=21,129), remdesivir (n=1,428) and both combined (n=10,846) associated with a lower frequency of neurological complications: OR=0.76 (95% CI=0.69-0.83), OR 0.69 (95% CI=0.51-0.90) and OR=0.54, (95% CI=0.47-0.61) respectively. In non-hypoxic COVID-19, dexamethasone (n=2,580) associated with less neurological complications (OR=0.78, 95% CI 0.62-0.97), while the dexamethasone/remdesivir combination (n=460) showed a similar trend (OR=0.63, 95% CI=0.31-1.15). INTERPRETATION: Treatment with dexamethasone, remdesivir or both in patients hospitalised with COVID-19 associated with a lower frequency of neurological complications in an additive manner, such that the greatest benefit was observed in patients who received both drugs together.

Type: Article
Title: Fewer COVID-19 neurological complications with dexamethasone and remdesivir
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/ana.26536
Publisher version: http://doi.org/10.1002/ana.26536
Language: English
Additional information: Copyright © 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: ISARIC4C investigators
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10158638
Downloads since deposit
34Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item